HAYWARD, Calif.--(BUSINESS WIRE)--Feb. 10, 2004--IMPAX
Laboratories Inc. (Nasdaq:IPXL) today announced that the Company has
postponed the release of its fourth quarter 2003 financial results to
Tuesday, February 17, 2004, to permit additional time for the
Company's newly appointed independent auditors to complete their
review of the Company's 2003 fourth quarter and year-end financial
statements. Results were originally scheduled to be announced on
Wednesday, February 11, 2004.
Barry R. Edwards, Chief Executive Officer, and Cornel C. Spiegler,
Chief Financial Officer, will host an investment conference call
beginning at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) on
February 17 to discuss these results and to answer questions.
To participate in the live call by telephone, please dial
888-803-7396 from the U.S., or for international callers, please dial
706-634-1052.
Those interested in listening to the conference call live via the
Internet may do so by visiting the Company's Web site at
www.impaxlabs.com. To listen to the live call, please go to the Web
site 15 minutes prior to its start to register, download, and install
the necessary audio software.
A replay will be available on the Company Web site for 14 days
beginning February 17, 2004. A telephone replay will be available from
11:30 a.m. Eastern Time February 17 through 11:59 p.m. Eastern Time
February 19, by dialing 800-642-1687 from the U.S., or 706-645-9291
for international callers, and entering conference ID number 5330780.
IMPAX Laboratories, Inc. is a technology based specialty
pharmaceutical company applying its formulation expertise and drug
delivery technology to the development of controlled-release and
specialty generics in addition to the development of branded products.
IMPAX markets its generic products through its Global Pharmaceuticals
division and intends to market its branded products through the IMPAX
Pharmaceuticals division. Additionally, where strategically
appropriate, IMPAX has developed marketing partnerships to fully
leverage its technology platform. IMPAX Laboratories is headquartered
in Hayward, California, and has a full range of capabilities in its
Hayward and Philadelphia facilities. For more information, please
visit the Company's Web site at: www.impaxlabs.com.
"Safe Harbor" statement under the Private Securities Litigation
Reform Act of 1995:
To the extent any statements made in this news release contain
information that is not historical, these statements are
forward-looking in nature and express the beliefs and expectations of
management. Such statements are based on current expectations and
involve a number of known and unknown risks and uncertainties that
could cause IMPAX's future results, performance or achievements to
differ significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Such risks
and uncertainties include, but are not limited to, IMPAX's ability to
complete the private placement on the terms contemplated or at all,
IMPAX's ability to obtain sufficient capital to fund its operations,
the difficulty of predicting FDA filings and approvals, consumer
acceptance and demand for new pharmaceutical products, the impact of
competitive products and pricing, IMPAX's ability to successfully
develop and commercialize pharmaceutical products, IMPAX's reliance on
key strategic alliances, the uncertainty of patent litigation, the
availability of raw materials, the regulatory environment, dependence
on patent and other protection for innovative products, exposure to
product liability claims, fluctuations in operating results and other
risks detailed from time to time in IMPAX's filings with the
Securities and Exchange Commission. Forward-looking statements speak
only as to the date on which they are made, and IMPAX undertakes no
obligation to update publicly or revise any forward-looking statement,
regardless of whether new information becomes available, future
developments occur or otherwise.
CONTACT: IMPAX Laboratories, Inc.
Barry R. Edwards (CEO), 215-289-2220 Ext. 1771
Larry Hsu, Ph.D. (President), 510-476-2000 Ext. 1111
Cornel C. Spiegler (CFO), 215-289-2220 Ext. 1706
www.impaxlabs.com
or
Investor Relations:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz, 212-838-3777 (kgolodetz@lhai.com)
Bruce Voss, 310-691-7100 (bvoss@lhai.com)
www.lhai.com
SOURCE: IMPAX Laboratories, Inc.